Harbour Trust & Investment Management Co Buys 484 Shares of Stryker Co. (NYSE:SYK)

Harbour Trust & Investment Management Co lifted its position in Stryker Co. (NYSE:SYK) by 1.1% during the 4th quarter, Holdings Channel reports. The firm owned 42,831 shares of the medical technology company’s stock after acquiring an additional 484 shares during the period. Stryker comprises about 1.8% of Harbour Trust & Investment Management Co’s holdings, making the stock its 14th biggest holding. Harbour Trust & Investment Management Co’s holdings in Stryker were worth $15,421,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in the company. Dunhill Financial LLC raised its holdings in Stryker by 94.9% in the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after purchasing an additional 37 shares in the last quarter. Darwin Wealth Management LLC bought a new stake in shares of Stryker in the 3rd quarter worth approximately $36,000. Activest Wealth Management purchased a new stake in shares of Stryker in the 4th quarter worth approximately $36,000. Crews Bank & Trust purchased a new stake in shares of Stryker in the fourth quarter worth $39,000. Finally, Hara Capital LLC bought a new position in shares of Stryker during the third quarter valued at $42,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Stryker

In other news, Director Ronda E. Stryker sold 201,392 shares of the company’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the sale, the director now directly owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. This represents a 5.24 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.90% of the stock is owned by company insiders.

Stryker Stock Performance

Shares of NYSE SYK opened at $391.42 on Monday. The firm’s fifty day moving average is $377.23 and its two-hundred day moving average is $364.97. Stryker Co. has a 52-week low of $314.93 and a 52-week high of $406.19. The company has a market cap of $149.22 billion, a P/E ratio of 50.44, a P/E/G ratio of 2.98 and a beta of 0.96. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter last year, the firm earned $3.46 earnings per share. As a group, analysts anticipate that Stryker Co. will post 13.49 EPS for the current fiscal year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be paid a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 0.86%. The ex-dividend date of this dividend is Monday, March 31st. Stryker’s payout ratio is 43.30%.

Analysts Set New Price Targets

A number of research firms have weighed in on SYK. UBS Group raised their price objective on shares of Stryker from $366.00 to $370.00 and gave the company a “neutral” rating in a research note on Wednesday, October 30th. Barclays boosted their price objective on shares of Stryker from $402.00 to $418.00 and gave the stock an “overweight” rating in a report on Thursday, October 31st. Piper Sandler reaffirmed an “overweight” rating and set a $420.00 price objective (up from $380.00) on shares of Stryker in a research report on Wednesday, October 30th. Robert W. Baird boosted their target price on Stryker from $378.00 to $405.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 30th. Finally, Stifel Nicolaus increased their price objective on shares of Stryker from $400.00 to $440.00 and gave the company a “buy” rating in a research report on Wednesday, January 29th. Five equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $419.37.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.